759 THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDYDavid T. Rubin, Axel Dignaß, Jessica R. Allegretti et al.|Gastroenterology|2024Cited by 14
913b THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDYJessica R. Allegretti, David T. Rubin, Laurent Peyrin‐Biroulet et al.|Gastroenterology|2023Cited by 9
Tu1446: THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 2B QUASAR STUDY RESULTS THROUGH WEEK 12Jessica R. Allegretti, Axel Dignaß, Brian G. Feagan et al.|Gastroenterology|2022Cited by 0
Su1862 GUSELKUMAB IMPROVES SYMPTOMS OF FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12Axel Dignaß, Jessica R. Allegretti, Brian Bressler et al.|Gastroenterology|2024Cited by 0